Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Douglas Marchion"'
Autor:
Yu Cao, Jimena Trillo-Tinoco, Rosa A. Sierra, Carmen Anadon, Wenjie Dai, Eslam Mohamed, Ling Cen, Tara L. Costich, Anthony Magliocco, Douglas Marchion, Richard Klar, Sven Michel, Frank Jaschinski, Richard R. Reich, Shikhar Mehrotra, Juan R. Cubillos-Ruiz, David H. Munn, Jose R. Conejo-Garcia, Paulo C. Rodriguez
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
T-cell function impairment is one of the major determinants of tumour immune evasion. Here, the authors show that the hostile conditions in the tumour microenvironment lead to C/EBP homologous-protein upregulation in T cells via ER stress, resulting
Externí odkaz:
https://doaj.org/article/f05c7d9780cc4100b5638fc324c1bb21
Autor:
Pamela N. Munster, Daniel M. Sullivan, Anthony Neuger, Richard Lush, Frederick A. Hausheer, Sem Bastien, Douglas Marchion, Elona Bicaku, Ronald C. DeConti, Jana Dawson, Adil I. Daud
Supplementary Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d9697e5388a426a347a91ff8cd34505
https://doi.org/10.1158/1078-0432.22440090
https://doi.org/10.1158/1078-0432.22440090
Autor:
Pamela N. Munster, Daniel M. Sullivan, Anthony Neuger, Richard Lush, Frederick A. Hausheer, Sem Bastien, Douglas Marchion, Elona Bicaku, Ronald C. DeConti, Jana Dawson, Adil I. Daud
Purpose: The novel topoisomerase I inhibitor karenitecin (KTN) shows activity against melanoma. We examined whether histone deacetylase inhibition could potentiate the DNA strand cleavage, cytotoxicity as well as the clinical toxicity, and efficacy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6efe0e46b300c1561e799201cc208254
https://doi.org/10.1158/1078-0432.c.6517464.v1
https://doi.org/10.1158/1078-0432.c.6517464.v1
Autor:
Carmen M. Anadon, Xiaoqing Yu, Kay Hänggi, Subir Biswas, Ricardo A. Chaurio, Alexandra Martin, Kyle K. Payne, Gunjan Mandal, Patrick Innamarato, Carly M. Harro, Jessica A. Mine, Kimberly B. Sprenger, Carla Cortina, John J. Powers, Tara Lee Costich, Bradford A. Perez, Chandler D. Gatenbee, Sandhya Prabhakaran, Douglas Marchion, Mirjam H.M. Heemskerk, Tyler J. Curiel, Alexander R. Anderson, Robert M. Wenham, Paulo C. Rodriguez, Jose R. Conejo-Garcia
Publikováno v:
Cancer Cell, 40(5), 545-+. CELL PRESS
Despite repeated associations between T cell infiltration and outcome, human ovarian cancer remains poorly responsive to immunotherapy. We report that the hallmarks of tumor recognition in ovarian cancer-infiltrating T cells are primarily restricted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57721682788ee4a832531d9545972589
https://hdl.handle.net/1887/3566435
https://hdl.handle.net/1887/3566435
Autor:
Carmen M. Anadon, Shelley S. Tworoger, Alexander R. A. Anderson, Robert M. Wenham, Ricardo A. Chaurio, Mary K. Townsend, Paulo C. Rodriguez, Xiaoqing Yu, Naoko Sasamoto, Carlos Moran, Andrea L. Buras, Jimena Trillo-Tinoco, Tara Lee Costich, Jose R. Conejo-Garcia, Jessica A. Mine, Subir Biswas, Chandler Gatenbee, Kathryn L. Terry, Kristen E. Rigolizzo, Douglas Marchion, Kyle K. Payne, Gunjan Mandal, Carly M. Harro
Publikováno v:
Nature. 591:464-470
Most ovarian cancers are infiltrated by prognostically relevant activated T cells1–3, yet exhibit low response rates to immune checkpoint inhibitors4. Memory B cell and plasma cell infiltrates have previously been associated with better outcomes in
Autor:
Yu Cao, Jimena Trillo-Tinoco, Rosa A. Sierra, Carmen Anadon, Wenjie Dai, Eslam Mohamed, Ling Cen, Tara L. Costich, Anthony Magliocco, Douglas Marchion, Richard Klar, Sven Michel, Frank Jaschinski, Richard R. Reich, Shikhar Mehrotra, Juan R. Cubillos-Ruiz, David H. Munn, Jose R. Conejo-Garcia, Paulo C. Rodriguez
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-1 (2019)
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Externí odkaz:
https://doaj.org/article/abe981cf7a3943d19915317c7bf25947
Autor:
Ou Deng, Sweta Dash, Thales C. Nepomuceno, Bin Fang, Sang Y. Yun, Eric A. Welsh, Harshani R. Lawrence, Douglas Marchion, John M. Koomen, Alvaro N. Monteiro, Uwe Rix
Publikováno v:
Journal of Biological Chemistry. 298:102550
BRCA1/2-deficient ovarian carcinoma (OC) has been shown to be particularly sensitive to poly (ADP-ribose) polymerase inhibitors (PARPis). Furthermore, BRCA1/2 mutation status is currently used as a predictive biomarker for PARPi therapy. Despite prov
Autor:
Sumit Mehta, Subir Biswas, Gunjan Mandal, Alexandra Martin, Naoko Sasamoto, Kathryn Terry, Douglas Marchion, Mary Townsend, Shelley Tworoger, Robert Wenham, Jose Conejo-Garcia
Publikováno v:
Gynecologic Oncology. 166:S127
Autor:
Ou Deng, Sweta Dash, Thales Nepomuceno, Bin Fang, Douglas Marchion, John Koomen, Alvaro N. Monteiro, Uwe Rix
Publikováno v:
Molecular Cancer Therapeutics. 20:P018-P018
Background: About 40-50% of epithelial ovarian cancers (EOC) show defects in DNA repair by homologous recombination (HR), which are mostly associated with BRCA1/2 loss-of-function mutations. The PARP inhibitors (PARPis) olaparib, niraparib and rucapa
Autor:
Hu, Chen, Zhang, Mu, Moses, Niko, Hu, Cong-li, Polin, Lisa, Chen, Wei, Jang, Hyejeong, Heyza, Joshua, Malysa, Agnes, Caruso, Joseph A., Xiang, Shengyan, Patrick, Steve, Stemmer, Paul, Lou, Zhenkun, Bai, Wenlong, Wang, Chuangui, Bepler, Gerold, Zhang, Xiaohong Mary
Publikováno v:
Cell Death & Disease; May2020, Vol. 11 Issue 5, p1-18, 18p